Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0MAQFZ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CPO-102
|
|||||
| Synonyms |
CPO102; CPO 102; Claudin 18.2-MMAE ADC
Click to Show/Hide
|
|||||
| Organization |
Conjupro Bioerapecitics, Inc.; CSPC Pharmaceutical Group Ltd.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 2 Indication(s)
Gastric cancer [ICD11:2B72]
Phase 1
Pancreatic cancer [ICD11:2C10]
Phase 1
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Claudin-18.2 (CLDN18.2)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.